PERSON
Purdue Pharma’s $7.4 Billion Opioid Settlement and Bankruptcy Filing
Purdue Pharma, Sackler family, opioid crisis, bankruptcy, settlement, OxyContin
Immunovant Shifts Focus to Next-Gen Drug Despite Positive Phase 3 Results for Batoclimab in Myasthenia Gravis
Immunovant, batoclimab, myasthenia gravis, Phase 3 success, IMVT-1402, FcRn inhibitor, autoimmune disorders
Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand
Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook
Otsuka’s Taiho pays $400M for Swiss partner to ‘turbocharge’ 3 ADCs to clinic
Araris, Taiho, Antibody-Drug Conjugates, Otsuka ‘s, Acquisition (action), ADCs, ADC
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera
White House pulls Weldon’s nomination to lead CDC at last minute
Weldon, nomination, Centers for Disease Control and Prevention (U.S.), Confirmation, Vaccines, Weldon ‘s, Senate
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
Trump blog: FDA, NIH picks clear Senate panel; FDA top lawyer resigns
United States Food and Drug Administration, NIH Mouse, Senate
FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
FDA, medical review, drug approval, device regulation, staff cuts, Elon Musk, DOGE, government efficiency
AbbVie’s New CEO Rob Michael Earns $18.5M in First Year as Humira Succession Plan Unfolds
AbbVie CEO succession, Rob Michael compensation, Humira patent expiration, Skyrizi and Rinvoq growth, Pharmaceutical executive pay